Investors

PediatRx, Inc., (PEDX.OB), is a specialty pharmaceutical company that brings prescription, branded products to healthcare professionals for the treatment of serious medical conditions treated in hospital, with an initial focus on oncology supportive care. The company has acquired the rights to GRANISOL® (granisetron HCl) Oral Solution from Cypress Pharmaceutical and is marketing the product to key customers via a focused channel strategy.

PediatRx is focused on providing Kidpliant™ branded, prescription medicines within the therapeutic categories targeted. In keeping with its mission, the company is identifying underserved pediatric market opportunities in these areas and is in the process of acquiring new products/opportunities and building a small, capitally-efficient and highly productive, focused sales and marketing team.

With recent changes in the regulatory landscape regarding pediatric pharmaceuticals, the company believes that the opportunities are many and growing, and it is well positioned to take full advantage of these opportunities in an area of high unmet need, emotive dynamics and no direct competitors.

Email: ir@pediatrx.com